BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
aheadofprint
Résumé
Drivers of Spitz neoplasms include activating point mutations in HRAS and Spitz-associated genomic fusions. It has become evident that some BRAF-mutated melanocytic neoplasms can morphologically mimic Spitz tumors (STs). These have been termed BRAF mutated and morphologically spitzoid (BAMS). In this study, 17 experts from the International Melanoma Pathology Study Group assessed 54 cases which included 40 BAMS and 14 true STs. The participants reviewed the cases blinded to the genomic data and selected among several diagnostic options, including BAMS, ST, melanoma, and other. A total of 38% of all diagnostic selections in the BAMS cases were for BAMS, whereas 32% were for ST. In 22 of the BAMS cases, the favored diagnosis was BAMS, whereas in 17 of the BAMS cases, the favored diagnosis was ST. Among the 20 cases in the total group of 54 with the highest number of votes for ST, half were BAMS. Of BAMS, 75% had a number of votes for ST that was within the SD of votes for ST seen among true ST cases. There was poor interobserver agreement for the precise diagnosis of the BAMS (kappa = 0.16) but good agreement that these cases were not melanoma (kappa = 0.7). BAMS nevi/tumors can closely mimic Spitz neoplasms. Expert melanoma pathologists in this study favored a diagnosis of ST in nearly half of the BAMS cases. There are BAMS cases that even experts cannot morphologically distinguish from true Spitz neoplasms.
Identifiants
pubmed: 38525831
doi: 10.1097/PAS.0000000000002194
pii: 00000478-990000000-00317
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: P.G. has served as a consultant for Castle Biosciences and has received royalties for textbooks from Elsevier. For the remaining authors, none were declared.
Références
Elder DE, Bastian BC, Cree IA, et al. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 2020;144:500–522.
Zhao J, Benton S, Zhang B, et al. Benign and intermediate-grade melanocytic tumors with BRAF mutations and spitzoid morphology: a subset of melanocytic neoplasms distinct from melanoma. Am J Surg Pathol. 2022;46:476–485.
Roh MR, Eliades P, Gupta S, et al. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015;28:661–672.
Quan VL, Zhang B, Zhang Y, et al. Integrating next-generation sequencing with morphology improves prognostic and biologic classification of spitz neoplasms. J Invest Dermatol. 2020;140:1599–1608.
Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the melanocytic pathology assessment tool and hierarchy for diagnosis classification schema for melanocytic lesions: a consensus statement. JAMA Netw Open. 2023;6:e2250613.
Wiesner T, Kutzner H, Cerroni L, et al. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology. 2016;48:113–131.
Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
Zembowicz A. Blue nevi and related tumors. Clin Lab Med. 2017;37:401–415.
Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37:676–684.
Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146–1156.
Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012;36:808–817.
Gerami P, Cooper C, Bajaj S, et al. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37:1387–1394.
Beaubier N, Tell R, Huether R, et al. Clinical validation of the Tempus xO assay. Oncotarget. 2018;9:25826–25832.
Beaubier N, Tell R, Lau D, et al. Clinical validation of the Tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019;10:2384–2396.
Randolph JJ. Free-Marginal Multirater Kappa (multirater kfree): an alternative to Fleiss’ Fixed Marginal Multirater Kappa. Adv Data Anal Classif. 2010;4:1–20.
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276–282.
Hagstrom M, Fumero-Velázquez M, Dhillon S, et al. An update on genomic aberrations in Spitz naevi and tumours. Pathology. 2023;55:196–205.
Zhang AJ, Rush PS, Tsao H, et al. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol. 2019;46:965–972.
Yeh I, Busam KJ. Spitz melanocytic tumours—a review. Histopathology. 2022;80:122–134.
Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61–65.
Cheng TW, Ahern MC, Giubellino A. The spectrum of spitz melanocytic lesions: from morphologic diagnosis to molecular classification. Front Oncol. 2022;12:1–24.